Across TCGA pan-cancer cohorts, LRRC74B Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated LRRC74B data layer compared with 19 for mass-spec protein.

The strongest signal is observed in breast invasive carcinoma (BRCA), where higher LRRC74B Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated LRRC74B expression acts as an unfavorable survival marker.

BRCA, CHOL, and ESCA are the cancer types where LRRC74B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BRCA	OS	Median	All	0.162	0.924	<.001	12	view →
CHOL	DFS	Median	All	0.037	0.486	.001	6	view →
ESCA	OS	Median	All	0.147	0.700	.002	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: LRRC74B tumor-vs-normal RNA expression · all LRRC74B data types